Regular and extended-release formulations of zolpidem [Ambien and Ambien CR; sanofi-aventis] have been granted paediatric exclusivity by the US FDA.

Source: Inpharma, Volume 1, Number 1567, 2006-12-09 , pp. 22-22(1)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: Children; Controlled-release-drugs; Development-status; Insomnia, treatment; Product-approvals; Zolpidem, therapeutic use

Document Type: Short communication

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$37.95 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A